Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current guidelines in heart failure management.

Jean-Bernard Durand1

  • 1Department of Medicine, University of Texas, MD Anderson Cancer Center, Houston, USA. jdurand@mdanderson.org

Ethnicity & Disease
|March 27, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pulmonary artery pressure via endobronchial ultrasound: A feasibility and safety study.

JTCVS techniques·2025
Same author

Safety of Contemporary Radiation Therapy in Patients With Cardiac Implantable Electronic Devices: Implications for Clinical Practice.

Journal of the American Heart Association·2025
Same author

CardioMEMS guided heart failure management in cardio-oncology patients: a tertiary care cancer center experience.

Cardio-oncology (London, England)·2025
Same author

Correlation of Natriuretic Peptides with Invasively Measured Intracardiac Filling Pressures in Patients With Cancer.

JACC. CardioOncology·2025
Same author

Pacing Solutions for Immune Checkpoint Myocarditis and Associated Conduction Disorders.

JACC. Case reports·2025
Same author

Endobronchial ultrasound: A novel screening test for pulmonary hypertension prior to major pulmonary surgery.

JTCVS techniques·2024
Same journal

Impact of Patient Race on Cataract Surgery Outcomes in a Safety Net Academic Medical Center.

Ethnicity & disease·2026
Same journal

Maternal Education-Related Patterns of Early Preterm Birth Rates: The Impact of Paternal Acknowledgment.

Ethnicity & disease·2026
Same journal

The Association of Race and Ethnicity with Six-Minute Walk Distance: The Multi-Ethnic Study of Atherosclerosis.

Ethnicity & disease·2026
Same journal

The Interplay of Neighborhood Deprivation, Race, and Multiple Sclerosis.

Ethnicity & disease·2026
Same journal

Exploring Dementia Awareness, Beliefs, and Attitudes among Asian Indian Immigrants in the United States.

Ethnicity & disease·2026
Same journal

Community Perspectives on Factors That Improve Young Men's Participation in Rural Research.

Ethnicity & disease·2026
See all related articles

Heart failure (HF) treatment guidelines recommend ACE inhibitors for HF with LVSD. Beta-blockers and spironolactone offer additional benefits for specific HF classes, improving patient outcomes.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Heart failure (HF) with left ventricular systolic dysfunction (LVSD) is a significant clinical challenge.
  • Current therapeutic strategies aim to improve symptoms and long-term prognosis.

Purpose of the Study:

  • To summarize current evidence-based recommendations for pharmacologic management of HF.
  • To outline the roles of key drug classes in treating HF patients.

Main Methods:

  • Review of established clinical practice guidelines for HF management.
  • Synthesis of data on the efficacy and safety of ACE inhibitors, ARBs, spironolactone, and beta-blockers.

Main Results:

  • ACE inhibitors are first-line therapy for HF (Class I-IV) with LVSD.

Related Experiment Videos

  • Angiotensin receptor blockers (ARBs) are alternatives for ACE inhibitor-intolerant patients.
  • Spironolactone offers added benefit in Class IV HF.
  • Beta-blockers (carvedilol, metoprolol) are indicated for Class II-III HF as add-on therapy.
  • Carvedilol demonstrates safety and efficacy in severe HF and post-MI LVSD.

    • Conclusions:

    • Pharmacologic therapy for HF involves a stepwise approach based on disease severity and patient characteristics.
    • Specific drug classes, including ACE inhibitors, ARBs, spironolactone, and beta-blockers, play crucial roles in optimizing HF management.
    • Evidence supports the use of carvedilol in severe HF and post-myocardial infarction LVSD.